NGS for Cancer Drug Development
Conference - Boston, MA, United States
Whatever your motivations, NGS for Cancer Drug Development is the only North American meeting this year that can truly deliver the answers.
The FDA outlines the practical utility of RNA-Seq when compared to microarray technology for maximum accuracy of gene expression measurement in tumor samples
Merck shows how big pharma are integrating NGS at the earliest stage in clinical trial design and how you can follow suit to serve your specific research aims
Cancer Institute of New Jersey shows off gold standard bioinformatics techniques for effective data analysis and interpretation for maximum performance in the clinic
AstraZeneca presents the answers to optimizing biomarker discovery and target validation through streamlined data application and integration techniques
Millennium explores the promise of NGS in cancer drug development for better patient selection and treatment decisions in the path towards personalized medicine
Dana-Farber Cancer Institute provides case studies for variant and mutation detection from screening of NGS data
Organization: Hanson Wade Ltd
(Courtesy of NGS for Cancer Drug Development, via blueseq.com)
NGS for Cancer Drug Development
Tue, Sep 24, 2013 - Thu, Sep 26, 2013
Hyatt Regency
One Avenue de Lafayette, Boston, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
